The Hindu Business Line : Glenmark asthma compound trials

Glenmark Pharmaceuticals Ltd has started the second phase of human trials on its lead molecule Oglemilast (GRC 3886) targeting asthma. The study to evaluate the efficacy of Oglemilast in the treatment of asthma will enrol approximately 230 patients in about 30 centres, a note from the company said. Oglemilast is at present also being studied in patients for Chronic Obstructive Pulmonary Disorder in a multi-center Phase II trial by Forest Laboratories Inc, the licensee for Oglemilast in North America. The first novel compound from the Mumbai-based drug-maker, Glenmark had entered into $190-million collaboration with Forest Labs in September 2004 for the development and commercialisation of this compound in the North American market. And when the compound does indeed get commercialised, Glenmark is also eligible to get royalty payments from Forest on net sales of the product, besides being the supplier of the active pharmaceutical ingredient to Forest. Glenmark has a similar collaboration agreement for Oglemilast with Teijin Pharma Limited for the Japanese market. Glenmark shares were marginally up, at Rs 357 on the BSE. - Our Bureau

More Stories on : Research & Development | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Glenmark asthma compound trials

Rasi Seeds sets up Rs 10-cr research facility

Opto Circuits drops acquisition

Setback for Orient Express’ dissident shareholders

Bharat Forge, IIT-B ink pact

SMS Pharma commissions plant for oncology APIs

Hindustan Sanitaryware plans acquisitions in Europe

Aurobindo drug gets US nod

Matrix, Aspen pact for divestment

AMW lowers sales target by 9,000 units